{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,2,1]],"date-time":"2025-02-01T05:33:21Z","timestamp":1738388001989,"version":"3.35.0"},"reference-count":35,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2025,1,3]],"date-time":"2025-01-03T00:00:00Z","timestamp":1735862400000},"content-version":"vor","delay-in-days":2,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Dermatol Ther (Heidelb)"],"published-print":{"date-parts":[[2025,1]]},"DOI":"10.1007\/s13555-024-01326-6","type":"journal-article","created":{"date-parts":[[2025,1,3]],"date-time":"2025-01-03T06:35:29Z","timestamp":1735886129000},"page":"237-244","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Two Patients with Therapy-Resistant Pemphigus Vulgaris and Severe Underlying Disease Showing Good Response to a New IVIg Preparation"],"prefix":"10.1007","volume":"15","author":[{"given":"Katharina","family":"Hogrefe","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Julia K.","family":"Winkler","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1816-421X","authenticated-orcid":false,"given":"Alexander H.","family":"Enk","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,1,3]]},"reference":[{"key":"1326_CR1","unstructured":"Ingold CJ, Sathe NC, Khan MAB. Pemphigus vulgaris. Treasure Island (FL): StatPearls; 2024."},{"issue":"11","key":"1326_CR2","doi-asserted-by":"publisher","first-page":"880","DOI":"10.1111\/cup.12384","volume":"41","author":"C Ohata","year":"2014","unstructured":"Ohata C, Ishii N, Furumura M. Locations of acantholysis in pemphigus vulgaris and pemphigus foliaceus. J Cutan Pathol. 2014;41(11):880\u20139.","journal-title":"J Cutan Pathol"},{"issue":"3","key":"1326_CR3","doi-asserted-by":"publisher","first-page":"264","DOI":"10.1590\/abd1806-4841.20199011","volume":"94","author":"AM Porro","year":"2019","unstructured":"Porro AM, Seque CA, Ferreira MCC, et al. Pemphigus vulgaris. An Bras Dermatol. 2019;94(3):264\u201378.","journal-title":"An Bras Dermatol"},{"issue":"2","key":"1326_CR4","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1111\/ajd.12422","volume":"57","author":"D Svecova","year":"2016","unstructured":"Svecova D. IVIG therapy in pemphigus vulgaris has corticosteroid-sparing and immunomodulatory effects. Australas J Dermatol. 2016;57(2):141\u20134.","journal-title":"Australas J Dermatol"},{"key":"1326_CR5","unstructured":"Arumugham VB, Rayi A. Intravenous immunoglobulin (IVIG). Treasure Island (FL): StatPearls; 2024."},{"key":"1326_CR6","first-page":"674","volume":"5","author":"SQ Nagelkerke","year":"2014","unstructured":"Nagelkerke SQ, Kuijpers TW. Immunomodulation by IVIg and the role of Fc-gamma receptors: classic mechanisms of action after all? Front Immunol. 2014;5:674.","journal-title":"Front Immunol"},{"issue":"3","key":"1326_CR7","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1111\/j.1346-8138.2009.00796.x","volume":"37","author":"Y Aoyama","year":"2010","unstructured":"Aoyama Y. What\u2019s new in i.v. immunoglobulin therapy and pemphigus: high-dose i.v. immunoglobulin therapy and its mode of action for treatment of pemphigus. J Dermatol. 2010;37(3):239\u201345.","journal-title":"J Dermatol"},{"issue":"1","key":"1326_CR8","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1111\/j.1423-0410.2009.01226.x","volume":"98","author":"M Radosevich","year":"2010","unstructured":"Radosevich M, Burnouf T. Intravenous immunoglobulin\u00a0G: trends in production methods, quality control and quality assurance. Vox Sang. 2010;98(1):12\u201328.","journal-title":"Vox Sang"},{"issue":"5","key":"1326_CR9","doi-asserted-by":"publisher","first-page":"494","DOI":"10.2340\/00015555-0900","volume":"90","author":"L Feldmeyer","year":"2010","unstructured":"Feldmeyer L, Benden C, Haile SR, et al. Not all intravenous immunoglobulin preparations are equally well tolerated. Acta Derm Venereol. 2010;90(5):494\u20137.","journal-title":"Acta Derm Venereol"},{"issue":"1","key":"1326_CR10","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1111\/j.1365-2249.2004.02412.x","volume":"136","author":"R Ameratunga","year":"2004","unstructured":"Ameratunga R, Sinclair J, Kolbe J. Increased risk of adverse events when changing intravenous immunoglobulin preparations. Clin Exp Immunol. 2004;136(1):111\u20133.","journal-title":"Clin Exp Immunol"},{"key":"1326_CR11","doi-asserted-by":"publisher","first-page":"1090","DOI":"10.3389\/fimmu.2019.01090","volume":"10","author":"JHO Hoffmann","year":"2019","unstructured":"Hoffmann JHO, Enk AH. High-dose intravenous immunoglobulin in skin autoimmune disease. Front Immunol. 2019;10:1090.","journal-title":"Front Immunol"},{"issue":"4","key":"1326_CR12","doi-asserted-by":"publisher","first-page":"595","DOI":"10.1016\/j.jaad.2008.09.052","volume":"60","author":"M Amagai","year":"2009","unstructured":"Amagai M, Ikeda S, Shimizu H, et al. A randomized double-blind trial of intravenous immunoglobulin for pemphigus. J Am Acad Dermatol. 2009;60(4):595\u2013603.","journal-title":"J Am Acad Dermatol"},{"issue":"5","key":"1326_CR13","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.2317762121","volume":"121","author":"AR Ahmed","year":"2024","unstructured":"Ahmed AR, Kalesinskas M, Kaveri SV. Restoring immune tolerance in pemphigus vulgaris. Proc Natl Acad Sci. 2024;121(5):e2317762121.","journal-title":"Proc Natl Acad Sci"},{"issue":"3","key":"1326_CR14","doi-asserted-by":"publisher","first-page":"346","DOI":"10.2340\/00015555-1471","volume":"93","author":"V Seidling","year":"2013","unstructured":"Seidling V, Hoffmann JH, Enk AH, Hadaschik EN. Analysis of high-dose intravenous immunoglobulin therapy in 16 patients with refractory autoimmune blistering skin disease: high efficacy and no serious adverse events. Acta Derm Venereol. 2013;93(3):346\u20139.","journal-title":"Acta Derm Venereol"},{"issue":"5","key":"1326_CR15","doi-asserted-by":"publisher","first-page":"548","DOI":"10.1111\/j.1468-3083.2006.01540.x","volume":"20","author":"S Baum","year":"2006","unstructured":"Baum S, Scope A, Barzilai A, Azizi E, Trau H. The role of IVIg treatment in severe pemphigus vulgaris. J Eur Acad Dermatol Venereol. 2006;20(5):548\u201352.","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"7","key":"1326_CR16","doi-asserted-by":"publisher","first-page":"1265","DOI":"10.3390\/medicina59071265","volume":"59","author":"MM Spalek","year":"2023","unstructured":"Spalek MM, Bowszyc-Dmochowska M, Dmochowski M. Intravenous immunoglobulin for autoimmune bullous diseases: a case series from a Central European referral center. Medicina (Kaunas). 2023;59(7):1265.","journal-title":"Medicina (Kaunas)"},{"issue":"3","key":"1326_CR17","doi-asserted-by":"publisher","first-page":"358","DOI":"10.1067\/mjd.2002.122735","volume":"47","author":"JC Bystryn","year":"2002","unstructured":"Bystryn JC, Jiao D, Natow S. Treatment of pemphigus with intravenous immunoglobulin. J Am Acad Dermatol. 2002;47(3):358\u201363.","journal-title":"J Am Acad Dermatol"},{"issue":"8","key":"1326_CR18","doi-asserted-by":"publisher","first-page":"944","DOI":"10.1111\/1346-8138.13341","volume":"43","author":"Y Otsuka","year":"2016","unstructured":"Otsuka Y, Ueno T, Yamase A, et al. Case of paraneoplastic pemphigus with immunoglobulin (Ig)G and IgA antibodies to various antigens. J Dermatol. 2016;43(8):944\u20136.","journal-title":"J Dermatol"},{"issue":"8","key":"1326_CR19","doi-asserted-by":"publisher","first-page":"503","DOI":"10.1111\/j.1346-8138.2007.00322.x","volume":"34","author":"X Zhu","year":"2007","unstructured":"Zhu X, Zhang B. Paraneoplastic pemphigus. J Dermatol. 2007;34(8):503\u201311.","journal-title":"J Dermatol"},{"key":"1326_CR20","doi-asserted-by":"crossref","unstructured":"Melnick LE, Beasley JM, Kim R, Brinster N, Sicco KL. Paraneoplastic pemphigus in a 34-year-old. Dermatol Online J. 2017;23(12):13030\/qt8sf4c5xn.","DOI":"10.5070\/D32312037677"},{"issue":"4","key":"1326_CR21","doi-asserted-by":"publisher","first-page":"388","DOI":"10.1590\/abd1806-4841.20199165","volume":"94","author":"CW Maruta","year":"2019","unstructured":"Maruta CW, Miyamoto D, Aoki V, et al. Paraneoplastic pemphigus: a clinical, laboratorial, and therapeutic overview. An Bras Dermatol. 2019;94(4):388\u201398.","journal-title":"An Bras Dermatol"},{"issue":"1","key":"1326_CR22","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1016\/j.autrev.2015.09.002","volume":"15","author":"P Cherin","year":"2016","unstructured":"Cherin P, Marie I, Michallet M, et al. Management of adverse events in the treatment of patients with immunoglobulin therapy: a review of evidence. Autoimmun Rev. 2016;15(1):71\u201381.","journal-title":"Autoimmun Rev"},{"issue":"2","key":"1326_CR23","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1111\/tme.12943","volume":"33","author":"J Demeter","year":"2023","unstructured":"Demeter J, Hamed A, L\u00e1szl\u00f3 S, et al. Efficacy and safety of BT595 (10% human intravenous immunoglobulin) in adult patients with chronic immune thrombocytopenia. Transfus Med. 2023;33(2):165\u201373.","journal-title":"Transfus Med"},{"issue":"3","key":"1326_CR24","doi-asserted-by":"publisher","first-page":"245","DOI":"10.1007\/s40268-023-00430-w","volume":"23","author":"C Duellberg","year":"2023","unstructured":"Duellberg C, Hannappel A, Kistner S, Maneg O. Biochemical characterization of a new 10% IVIG preparation [IgG next generation (BT595)\/Yimmugo(\u00ae)] obtained from a manufacturing process preserving IgA\/IgM potential of human plasma. Drugs R D. 2023;23(3):245\u201355.","journal-title":"Drugs R D"},{"issue":"16","key":"1326_CR25","doi-asserted-by":"publisher","first-page":"4073","DOI":"10.1016\/j.molimm.2008.07.012","volume":"45","author":"M Basta","year":"2008","unstructured":"Basta M. Ambivalent effect of immunoglobulins on the complement system: activation versus inhibition. Mol Immunol. 2008;45(16):4073\u20139.","journal-title":"Mol Immunol"},{"issue":"1","key":"1326_CR26","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1002\/1096-8652(200009)65:1<30::AID-AJH5>3.0.CO;2-J","volume":"65","author":"AS Wolberg","year":"2000","unstructured":"Wolberg AS, Kon RH, Monroe DM, Hoffman M. Coagulation factor XI is a contaminant in intravenous immunoglobulin preparations. Am J Hematol. 2000;65(1):30\u20134.","journal-title":"Am J Hematol"},{"issue":"10","key":"1326_CR27","first-page":"617","volume":"15","author":"B Sakem","year":"2013","unstructured":"Sakem B, Matozan K, Nydegger UE, Weigel G, Griesmacher A, Risch L. Anti-red blood cell antibodies, free light chains, and antiphospholipid antibodies in intravenous immunoglobulin preparations. Isr Med Assoc J. 2013;15(10):617\u201321.","journal-title":"Isr Med Assoc J"},{"issue":"3","key":"1326_CR28","doi-asserted-by":"publisher","first-page":"e626","DOI":"10.1542\/peds.2007-1218","volume":"121","author":"C Manlhiot","year":"2008","unstructured":"Manlhiot C, Tyrrell PN, Liang L, Atkinson AR, Lau W, Feldman BM. Safety of intravenous immunoglobulin in the treatment of juvenile dermatomyositis: adverse reactions are associated with immunoglobulin\u00a0A content. Pediatrics. 2008;121(3):e626\u201330.","journal-title":"Pediatrics"},{"issue":"4","key":"1326_CR29","doi-asserted-by":"publisher","first-page":"450","DOI":"10.1046\/j.1537-2995.1997.37497265353.x","volume":"37","author":"DF Friedman","year":"1997","unstructured":"Friedman DF, Lukas MB, Larson PJ, Douglas SD, Manno CS. Clinical impact of anti-D in intravenous immunoglobulin. Transfusion. 1997;37(4):450\u20132.","journal-title":"Transfusion"},{"issue":"2","key":"1326_CR30","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1046\/j.1423-0410.2003.00336.x","volume":"85","author":"SJ Thorpe","year":"2003","unstructured":"Thorpe SJ, Fox BJ, Dolman CD, Lawrence J, Thorpe R. Batches of intravenous immunoglobulin associated with adverse reactions in recipients contain atypically high anti-Rh D activity. Vox Sang. 2003;85(2):80\u20134.","journal-title":"Vox Sang"},{"key":"1326_CR31","doi-asserted-by":"publisher","first-page":"1299","DOI":"10.3389\/fimmu.2018.01299","volume":"9","author":"Y Guo","year":"2018","unstructured":"Guo Y, Tian X, Wang X, Xiao Z. Adverse effects of immunoglobulin therapy. Front Immunol. 2018;9:1299.","journal-title":"Front Immunol"},{"issue":"3","key":"1326_CR32","doi-asserted-by":"publisher","first-page":"171","DOI":"10.2165\/00002018-199921030-00003","volume":"21","author":"UE Nydegger","year":"1999","unstructured":"Nydegger UE, Sturzenegger M. Adverse effects of intravenous immunoglobulin therapy. Drug Saf. 1999;21(3):171\u201385.","journal-title":"Drug Saf"},{"issue":"10","key":"1326_CR33","doi-asserted-by":"publisher","first-page":"1460","DOI":"10.1046\/j.1537-2995.2003.00519.x","volume":"43","author":"I Knezevic-Maramica","year":"2003","unstructured":"Knezevic-Maramica I, Kruskall MS. Intravenous immune globulins: an update for clinicians. Transfusion. 2003;43(10):1460\u201380.","journal-title":"Transfusion"},{"issue":"3","key":"1326_CR34","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1159\/000056085","volume":"62","author":"Y Sherer","year":"2001","unstructured":"Sherer Y, Levy Y, Langevitz P, Rauova L, Fabrizzi F, Shoenfeld Y. Adverse effects of intravenous immunoglobulin therapy in 56 patients with autoimmune diseases. Pharmacology. 2001;62(3):133\u20137.","journal-title":"Pharmacology"},{"issue":"2","key":"1326_CR35","first-page":"139","volume":"19","author":"S Dashti-Khavidaki","year":"2009","unstructured":"Dashti-Khavidaki S, Aghamohammadi A, Farshadi F, et al. Adverse reactions of prophylactic intravenous immunoglobulin; a 13-year experience with 3004 infusions in Iranian patients with primary immunodeficiency diseases. J Investig Allergol Clin Immunol. 2009;19(2):139\u201345.","journal-title":"J Investig Allergol Clin Immunol"}],"container-title":["Dermatology and Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13555-024-01326-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s13555-024-01326-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13555-024-01326-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,1]],"date-time":"2025-02-01T03:30:00Z","timestamp":1738380600000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s13555-024-01326-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1]]},"references-count":35,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2025,1]]}},"alternative-id":["1326"],"URL":"https:\/\/doi.org\/10.1007\/s13555-024-01326-6","relation":{},"ISSN":["2193-8210","2190-9172"],"issn-type":[{"type":"print","value":"2193-8210"},{"type":"electronic","value":"2190-9172"}],"subject":[],"published":{"date-parts":[[2025,1]]},"assertion":[{"value":"12 November 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 December 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 January 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Alexander H. Enk received advisory board honoraria, consultancy fees and support for documenting history of illustrative patients from Biotest AG. Julia K. Winkler received travel expanse and honoraria from Biotest AG. Katharina Hogrefe declares to have no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"Written informed consent was obtained from the patients for publication of this case report and any accompanying images. Institutional review board was waived. The study was in accordance with the Declaration of Helsinki.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical Approval"}}]}}